{"id":"W4310595717","doi":"10.1007/s11523-022-00931-9","title":"Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Innovaderm (Canada)","funders":"Mirati Therapeutics","keywords":"Medicine; Nausea; Pharmacokinetics; Vomiting; Adverse effect; Internal medicine; Gastroenterology; Cancer; Response Evaluation Criteria in Solid Tumors; Capsule; Pharmacology; Chemotherapy; Progressive disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001028248,0.00149566,0.001921895,0.0003807507,0.0003978983,0.001127387,0.0007596466,0.001068767,0.003216608],"category_scores_gemma":[0.0005784453,0.0005876385,0.001714731,0.0004428407,0.0007839818,0.0007262463,0.00033781,0.003519338,0.0007485802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001133886,"about_ca_system_score_gemma":0.001904595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002689654,"about_ca_topic_score_gemma":0.008505329,"domain_scores_codex":[0.9997564,0.00009235429,0.000009250109,0.00004812122,0.0000201641,0.00007370201],"domain_scores_gemma":[0.9995314,0.00006065944,0.00006512235,0.00002471315,0.00002596445,0.0002920834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7593347,0.06410749,0.008784422,0.001091832,0.002854391,0.0004317677,0.0003159398,0.00702561,0.048992,0.0007069671,0.01079695,0.09555792],"study_design_scores_gemma":[0.6471391,0.3288106,0.01386907,0.00004530395,0.0008350133,0.0003460529,0.0001044306,0.001990606,0.00280202,0.0003121787,0.00370711,0.00003851135],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887862,0.002854874,0.0005748678,0.0009224809,0.0002127912,0.001763471,0.001997317,0.0001166162,0.002771394],"genre_scores_gemma":[0.9845341,0.003081286,0.001498782,0.001330432,0.0001745368,0.001390495,0.004373681,0.00004246159,0.003574138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003216608,"threshold_uncertainty_score":0.01076061,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01739782352627714,"score_gpt":0.3924252135381065,"score_spread":0.3750273900118293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}